Lessons from next-generation sequencing analysis in hematological malignancies

Por Braggio, E, Egan, J B, Fonseca, R, Stewart, A K
Publicado em 2013

Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context

Por Segges, P., Braggio, E., Minnicelli, C., Hassan, R., Zalcberg, I.R., Maiolino, A.
Publicado no Braz J Med Biol Res (2016)

Identification of three novel RB1 mutations in Brazilian patients with retinoblastoma by “exon by exon” PCR mediated SSCP analysis

Por Braggio, E, Bonvicino, C R, Vargas, F R, Ferman, S, Eisenberg, A L A, Seuánez, H N
Publicado em 2004

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

Por Miller, A, Asmann, Y, Cattaneo, L, Braggio, E, Keats, J, Auclair, D, Lonial, S, Russell, S J, Stewart, A K
Publicado no Blood Cancer J (2017)

Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression

Por Ojha, J, Secreto, C, Rabe, K, Ayres-Silva, J, Tschumper, R, Dyke, DV, Slager, S, Fonseca, R, Shanafelt, T, Kay, N, Braggio, E
Publicado no Leukemia (2014)

Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse

Por Braggio, E, Kay, NE, VanWier, S, Tschumper, RC, Smoley, S, Eckel-Passow, JE, Sassoon, T, Barrett, M, Van Dyke, DL, Byrd, JC, Jelinek, DF, Shanafelt, TD, Fonseca, R
Publicado em 2012

Genomic Characterization of High-Count MBL Cases Indicates that Early Detection of Driver Mutations and Subclonal Expansion are Predictors of Adverse Clinical Outcome

Por Barrio, S., Shanafelt, T. D., Ojha, J., Chaffee, K. G., Secreto, C., Kortüm, K. M., Pathangey, S., Van-Dyke, D. L., Slager, S. L., Fonseca, R., Kay, N. E., Braggio, E.
Publicado no Leukemia (2016)

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

Por Schmidt, J, Braggio, E, Kortuem, KM, Egan, JB, Zhu, YX, Xin, CS, Tiedemann, RE, Palmer, SE, Garbitt, VM, McCauley, D, Kauffman, M, Shacham, S, Chesi, M, Bergsagel, PL, Stewart, AK
Publicado em 2013

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

Por Kortuem, K M, Braggio, E, Bruins, L, Barrio, S, Shi, C S, Zhu, Y X, Tibes, R, Viswanatha, D, Votruba, P, Ahmann, G, Fonseca, R, Jedlowski, P, Schlam, I, Kumar, S, Bergsagel, P L, Stewart, A K
Publicado no Blood Cancer J (2016)

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma

Por Ansell, S M, Hodge, L S, Secreto, F J, Manske, M, Braggio, E, Price-Troska, T, Ziesmer, S, Li, Y, Johnson, S H, Hart, S N, Kocher, J-P A, Vasmatzis, G, Chanan-Kahn, A, Gertz, M, Fonseca, R, Dogan, A, Cerhan, J R, Novak, A J
Publicado em 2014

GENOME-WIDE ANALYSIS UNCOVERS RECURRENT ALTERATIONS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS (PCNSL)

Por Patrick O'Neill, Brian, Braggio, E., O'Neill, B.P., Van Wier, S, Ojha, J., McPhail, E., Asmann, Y., Egan, J., Ayres da Silva, J., Schiff, D., Lopes, M.B., Valdez, R., Tibes, R., Eckloff, B., Stewart, A.K., Fonseca, R.
Publicado em 2014

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

Por Bogenberger, J M, Kornblau, S M, Pierceall, W E, Lena, R, Chow, D, Shi, C-X, Mantei, J, Ahmann, G, Gonzales, I M, Choudhary, A, Valdez, R, Camoriano, J, Fauble, V, Tiedemann, R E, Qiu, Y H, Coombes, K R, Cardone, M, Braggio, E, Yin, H, Azorsa, D O, Mesa, R A, Stewart, A K, Tibes, R
Publicado em 2014